Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL811522 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| SCHEMBL352795 | 1.00 | ALDH1A1 (0.52) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL248092 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL913942 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Hydrochloric Acid SCHEMBL913941 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| Ammonia Solution, Strong SCHEMBL4826153 | 0.98 | ALDH1A1 (0.50) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| SCHEMBL30913865 | 0.94 | CA12 (0.53) | ALDH1A1HSD17B10ACHEMAPTTSHR | |
| SCHEMBL20303794 | 0.89 | L3MBTL1 (0.58) | ALDH1A1HSD17B10MAPTTSHRMAPK1 | |
| SCHEMBL21774543 | 0.89 | L3MBTL1 (0.58) | ALDH1A1HSD17B10MAPTTSHRMAPK1 | |
| SCHEMBL11813645 | 0.88 | LOXL2 (0.70) | ALDH1A1HSD17B10ACHEMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | DEVGEN NV (BE) | 2008-05-29 | — | — | US | claimed |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | DEVGEN NV (BE) | 2008-02-14 | — | — | US | claimed |
| EP-1838690-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | Devgen N.V. (BE) | 2007-10-03 | — | — | EP | claimed |
| EP-1819330-A1 | 5-CARBOXAMIDO SUBSTITUED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY | Devgen N.V. (BE) | 2007-08-22 | — | — | EP | claimed |
| WO-2006066879-A2 | COMPOUNDS WITH KV4 ION CHANNEL ACTIVITY | DEVGEN N.V. (BE) | 2006-06-29 | — | — | WO | claimed |
| WO-2006058905-A1 | 5-CARBOXAMIDO SUBSTITUTED THIAZOLE DERIVATIVES THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE Kv FAMILY | DEVGEN NV (BE) | 2006-06-08 | — | — | WO | claimed |
| US-5288900-A | Crystallization of optical isomers of leukotriene antagonists using (R)-4-nitro-α-methylbenezenemethonamine | SMITHKLINE BEECHAM CORPORATION (US) | 1994-02-22 | — | — | US | claimed |
| EP-0552254-A1 | CRYSTALLIZATION OF OPTICAL ISOMERS OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-28 | — | — | EP | claimed |
| WO-1992005151-A1 | CRYSTALLIZATION OF OPTICAL ISOMERS OF LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-04-02 | — | — | WO | claimed |
| US-4066658-A | RESOLUTION OF D,L-DEHYDROPROLINE | HOFFMANN-LA ROCHE INC. (US) | 1978-01-03 | — | — | US | claimed |
| US-3965121-A | Salts of the γ-lactone of (-)-threo-hydroxycitric acid with R(+)-α-methyl-p-nitrobenzylamine | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | claimed |
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| EP-4486390-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | Terremoto Biosciences, Inc (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12043602-B2 | Fendiline derivatives | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-01-11 | — | — | US | disclosed |
| US-4066658-A | RESOLUTION OF D,L-DEHYDROPROLINE | HOFFMANN-LA ROCHE INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-3988349-A | Salts of N-formyl-6-chlorotryptophan and α-methyl-p-nitrobenzylamine | HOFFMANN-LA ROCHE INC. (US) | 1976-10-26 | — | — | US | disclosed |
| US-3965121-A | Salts of the γ-lactone of (-)-threo-hydroxycitric acid with R(+)-α-methyl-p-nitrobenzylamine | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3965121-A | Salts of the γ-lactone of (-)-threo-hydroxycitric acid with R(+)-α-methyl-p-nitrobenzylamine | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3965129-A | THREO-EPOXYACONITIC ACID BIS-R(+)-ALPHA-METHYL-P-NITROBENZYLAMINE SALT | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115600-A1 | COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT1S1, AKT2 | ALDH1A1 4472/4885HSD17B10 2922/4885ACHE 3854/4885 |
| US-12043602-B2 | Fendiline derivatives | CYP11B2, CYP3A7, CYP4F2 | ALDH1A1 292/4885HSD17B10 92/4885ACHE 859/4885 |
| US-20080039442-A1 | Compounds With Kv4 Ion Channel Activity | KCNA4, HCN4, KCNN4 | ALDH1A1 2549/4885HSD17B10 2419/4885ACHE 417/4885 |
| US-20240009169-A9 | PPARG Modulators for the Treatment of Osteoporosis | PPARG, PPARA, PPARD | ALDH1A1 4575/4885HSD17B10 2769/4885ACHE 4835/4885 |
| US-20080125432-A1 | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family | KCNA5, KCNA1, KCNJ2 | ALDH1A1 1395/4885HSD17B10 1866/4885ACHE 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.